This can be, at least partially, due to the fact that PTEN assessment lacks consistency and reproducibility across different studies in terms of the type of assay, antibodies used for immunohistochemistry testing, scoring system, cutoffs for PTEN-loss/low definition, and source of tumor samples (primary versus metastatic). The gene discussed is PTEN; the disease is neoplasm.